RU2003103596A - Носитель в виде частиц, предназначенный для улучшения перорального всасывания активных начал - Google Patents
Носитель в виде частиц, предназначенный для улучшения перорального всасывания активных начал Download PDFInfo
- Publication number
- RU2003103596A RU2003103596A RU2003103596/15A RU2003103596A RU2003103596A RU 2003103596 A RU2003103596 A RU 2003103596A RU 2003103596/15 A RU2003103596/15 A RU 2003103596/15A RU 2003103596 A RU2003103596 A RU 2003103596A RU 2003103596 A RU2003103596 A RU 2003103596A
- Authority
- RU
- Russia
- Prior art keywords
- carriers according
- polymer
- carriers
- active
- eudragit
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims 3
- 229920002851 polycationic polymer Polymers 0.000 claims abstract 5
- 229920002988 biodegradable polymer Polymers 0.000 claims abstract 4
- 239000004621 biodegradable polymer Substances 0.000 claims abstract 4
- 238000010521 absorption reaction Methods 0.000 claims abstract 2
- 239000011159 matrix material Substances 0.000 claims abstract 2
- 239000000969 carrier Substances 0.000 claims 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- ZAFFWOKULJCCSA-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate;trimethylazanium;chloride Chemical compound [Cl-].C[NH+](C)C.CCOC(=O)C(C)=C ZAFFWOKULJCCSA-UHFFFAOYSA-N 0.000 claims 2
- 229960002897 heparin Drugs 0.000 claims 2
- 229920000669 heparin Polymers 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 235000014655 lactic acid Nutrition 0.000 claims 2
- 239000004310 lactic acid Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920001610 polycaprolactone Polymers 0.000 claims 2
- 229920000728 polyester Polymers 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 229920001661 Chitosan Polymers 0.000 claims 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 claims 1
- 229920003152 Eudragit® RS polymer Polymers 0.000 claims 1
- 229920003134 Eudragit® polymer Polymers 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- 239000004952 Polyamide Substances 0.000 claims 1
- 229920002732 Polyanhydride Polymers 0.000 claims 1
- 108010039918 Polylysine Proteins 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 229940127215 low-molecular weight heparin Drugs 0.000 claims 1
- 125000005395 methacrylic acid group Chemical class 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 229920005615 natural polymer Polymers 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 229920002647 polyamide Polymers 0.000 claims 1
- 229920000515 polycarbonate Polymers 0.000 claims 1
- 239000004417 polycarbonate Substances 0.000 claims 1
- 229920000656 polylysine Polymers 0.000 claims 1
- 229920006324 polyoxymethylene Polymers 0.000 claims 1
- 229920002635 polyurethane Polymers 0.000 claims 1
- 239000004814 polyurethane Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
- Medicines Containing Plant Substances (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0008902A FR2811227A1 (fr) | 2000-07-07 | 2000-07-07 | Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs |
| FR00/08902 | 2000-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2003103596A true RU2003103596A (ru) | 2004-08-20 |
Family
ID=8852251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003103596/15A RU2003103596A (ru) | 2000-07-07 | 2001-07-05 | Носитель в виде частиц, предназначенный для улучшения перорального всасывания активных начал |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8052998B2 (https=) |
| EP (1) | EP1313453B1 (https=) |
| JP (1) | JP5175017B2 (https=) |
| KR (1) | KR20030038655A (https=) |
| CN (1) | CN1440277A (https=) |
| AT (1) | ATE395906T1 (https=) |
| AU (1) | AU2002218745A1 (https=) |
| BR (1) | BRPI0112080B1 (https=) |
| CA (1) | CA2415414C (https=) |
| DE (1) | DE60134147D1 (https=) |
| DK (1) | DK1313453T3 (https=) |
| ES (1) | ES2305121T3 (https=) |
| FR (1) | FR2811227A1 (https=) |
| MX (1) | MXPA03000193A (https=) |
| PT (1) | PT1313453E (https=) |
| RU (1) | RU2003103596A (https=) |
| WO (1) | WO2002003960A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8257744B2 (en) * | 2000-07-07 | 2012-09-04 | Laboratorios Farmacéuticos Rovi, S.A. | Pharmaceutical forms for the release of active compounds |
| EP2060253A1 (en) * | 2007-11-14 | 2009-05-20 | Laboratorios Farmaceuticos Rovi, S.A. | Pharmaceutical forms for the release of active compounds |
| BE1015608A6 (fr) * | 2003-07-15 | 2005-06-07 | Messadek Jallal | Traitement des arterites. |
| ES2278314T3 (es) * | 2003-04-17 | 2007-08-01 | Jallal Messadek | Formulaciones orales para la liberacion controlada de la betaina. |
| US20060128657A1 (en) * | 2003-08-04 | 2006-06-15 | Jallal Messadek | Selected betaines and their uses |
| WO2006088647A1 (en) * | 2005-02-17 | 2006-08-24 | Medivas, Llc | Polymer particle delivery compositions and methods of use |
| EP1730516A1 (en) * | 2004-03-30 | 2006-12-13 | Pfizer Products Incorporated | Method and device for evaluation of pharmaceutical compositions |
| BE1016128A6 (fr) * | 2004-07-22 | 2006-03-07 | Messadek Jallal | Combinaisons therapeutiques |
| WO2006050581A2 (en) * | 2004-11-10 | 2006-05-18 | Jallal Messadek | Betaine as agent against arthropod - or mosquito -borne diseases |
| ATE540690T1 (de) * | 2005-04-27 | 2012-01-15 | Jallal Messadek | Insulinkombinationen |
| JP5178520B2 (ja) | 2005-09-22 | 2013-04-10 | メディバス エルエルシー | 固体ポリマー送達組成物およびその使用法 |
| WO2008065502A1 (en) * | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein |
| WO2008125940A2 (en) * | 2007-04-17 | 2008-10-23 | Pfizer Products Inc. | Nanoparticles comprising non-crystalline drug |
| US8703204B2 (en) * | 2007-05-03 | 2014-04-22 | Bend Research, Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer |
| WO2008135852A2 (en) * | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Pharmaceutical compositions comprising nanoparticles and casein |
| US8309129B2 (en) * | 2007-05-03 | 2012-11-13 | Bend Research, Inc. | Nanoparticles comprising a drug, ethylcellulose, and a bile salt |
| WO2008149230A2 (en) | 2007-06-04 | 2008-12-11 | Pfizer Products Inc. | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate |
| EP2162120B1 (en) * | 2007-06-04 | 2016-05-04 | Bend Research, Inc | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer |
| US20100215747A1 (en) * | 2007-07-13 | 2010-08-26 | Corey Jay Bloom | Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers |
| US8802156B2 (en) | 2007-11-14 | 2014-08-12 | Laboratorios Farmacéuticos Rovi, S.A. | Pharmaceutical forms for the release of active compounds |
| EP2213282A1 (en) * | 2009-01-30 | 2010-08-04 | Laboratorios Farmaceuticos Rovi, S.A. | Pharmaceutical forms for the release of active compounds |
| WO2009065193A1 (en) * | 2007-11-21 | 2009-05-28 | Jallal Messadek | Treatment of aspirin resistance with betaine and/or betaine enriched molasses |
| WO2009073216A1 (en) * | 2007-12-06 | 2009-06-11 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer |
| EP2231169B1 (en) * | 2007-12-06 | 2016-05-04 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
| US9101547B2 (en) * | 2011-08-04 | 2015-08-11 | Nano And Advanced Materials Institute Limited | Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery |
| DE102012019029A1 (de) | 2012-09-27 | 2014-03-27 | Alf Lamprecht | Arzneiformulierungen zur oralen Gabe von therapeutischen Substanzen und Verfahren zur Herstellung |
| CA3015172A1 (en) | 2016-02-18 | 2017-08-24 | Privo Technologies, Inc. | Two-stage microparticle-based therapeutic delivery system and method |
| WO2018151849A1 (en) | 2017-02-17 | 2018-08-23 | Privo Technologies, Inc. | Particle-based multi-layer therapeutic delivery device and method |
| US10478403B1 (en) | 2017-05-03 | 2019-11-19 | Privo Technologies, Inc. | Intraoperative topically-applied non-implantable rapid release patch |
| KR20240041285A (ko) * | 2021-06-01 | 2024-03-29 | 프리보 테크놀로지스, 인코포레이티드 | 향상된 2단계 미세입자 기반 국소 치료제 전달 시스템 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT397345B (de) * | 1990-04-04 | 1994-03-25 | Chemiefaser Lenzing Ag | Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen |
| AU653771B2 (en) * | 1991-01-03 | 1994-10-13 | Alkermes Controlled Therapeutics, Inc. | Stabilization of proteins by cationic biopolymers |
| EP0535937B2 (en) * | 1991-10-01 | 2008-05-21 | Takeda Chemical Industries, Ltd. | Prolonged release microparticle preparation and production of the same |
| GB9202464D0 (en) * | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
| DE4220782A1 (de) * | 1992-06-25 | 1994-01-05 | Basf Ag | Verfahren zur Herstellung von festen pharmazeutischen Retardformen |
| US5401516A (en) * | 1992-12-21 | 1995-03-28 | Emisphere Technologies, Inc. | Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof |
| GB9412273D0 (en) * | 1994-06-18 | 1994-08-10 | Univ Nottingham | Administration means |
| CA2214889C (en) * | 1995-03-10 | 2005-05-24 | Hans Koll | Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and a process for the production thereof |
| US5686113A (en) * | 1995-03-21 | 1997-11-11 | Temple University Of The Commonwealth System Of Higher Education | Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses |
| FR2769853B1 (fr) * | 1997-10-21 | 2000-01-28 | Prographarm Lab | Nouveau procede d'obtention de microspheres et les produits ainsi realises |
| CZ20011629A3 (cs) * | 1998-11-12 | 2001-12-12 | Smithkline Beecham Plc | Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků |
| WO2000043044A1 (en) * | 1999-01-19 | 2000-07-27 | The Children's Hospital Of Philadelphia | Compositions and methods for controlled delivery of virus vectors |
-
2000
- 2000-07-07 FR FR0008902A patent/FR2811227A1/fr active Pending
-
2001
- 2001-07-05 AT AT01984141T patent/ATE395906T1/de active
- 2001-07-05 CA CA2415414A patent/CA2415414C/fr not_active Expired - Lifetime
- 2001-07-05 DE DE60134147T patent/DE60134147D1/de not_active Expired - Lifetime
- 2001-07-05 WO PCT/FR2001/002159 patent/WO2002003960A1/fr not_active Ceased
- 2001-07-05 AU AU2002218745A patent/AU2002218745A1/en not_active Abandoned
- 2001-07-05 ES ES01984141T patent/ES2305121T3/es not_active Expired - Lifetime
- 2001-07-05 KR KR10-2003-7000198A patent/KR20030038655A/ko not_active Withdrawn
- 2001-07-05 MX MXPA03000193A patent/MXPA03000193A/es active IP Right Grant
- 2001-07-05 EP EP01984141A patent/EP1313453B1/fr not_active Expired - Lifetime
- 2001-07-05 JP JP2002508415A patent/JP5175017B2/ja not_active Expired - Fee Related
- 2001-07-05 DK DK01984141T patent/DK1313453T3/da active
- 2001-07-05 PT PT01984141T patent/PT1313453E/pt unknown
- 2001-07-05 RU RU2003103596/15A patent/RU2003103596A/ru not_active Application Discontinuation
- 2001-07-05 CN CN01812448A patent/CN1440277A/zh active Pending
- 2001-07-05 BR BRPI0112080A patent/BRPI0112080B1/pt not_active IP Right Cessation
- 2001-07-05 US US10/332,351 patent/US8052998B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0112080B1 (pt) | 2017-01-24 |
| JP5175017B2 (ja) | 2013-04-03 |
| MXPA03000193A (es) | 2004-09-13 |
| PT1313453E (pt) | 2008-07-16 |
| DE60134147D1 (de) | 2008-07-03 |
| CA2415414C (fr) | 2011-08-23 |
| KR20030038655A (ko) | 2003-05-16 |
| EP1313453A1 (fr) | 2003-05-28 |
| ATE395906T1 (de) | 2008-06-15 |
| CN1440277A (zh) | 2003-09-03 |
| EP1313453B1 (fr) | 2008-05-21 |
| CA2415414A1 (fr) | 2002-01-17 |
| FR2811227A1 (fr) | 2002-01-11 |
| BR0112080A (pt) | 2003-05-06 |
| AU2002218745A1 (en) | 2002-01-21 |
| JP2004502720A (ja) | 2004-01-29 |
| US8052998B2 (en) | 2011-11-08 |
| US20050013866A1 (en) | 2005-01-20 |
| WO2002003960A1 (fr) | 2002-01-17 |
| ES2305121T3 (es) | 2008-11-01 |
| DK1313453T3 (da) | 2008-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003103596A (ru) | Носитель в виде частиц, предназначенный для улучшения перорального всасывания активных начал | |
| JP2004502720A5 (https=) | ||
| Saikia et al. | Chitosan: a promising biopolymer in drug delivery applications | |
| Kato et al. | Application of chitin and chitosan derivatives in the pharmaceutical field | |
| Jain et al. | Design and development of hydrogel beads for targeted drug delivery to the colon | |
| DE69927350T2 (de) | Wasserlösliche paclitaxel konjugate kombiniert mit bestrahlung zur behandlung von krebs | |
| US6264938B1 (en) | Combination therapy for treating hypercholestrolemia | |
| US6589548B1 (en) | Controlled drug delivery system using the conjugation of drug to biodegradable polyester | |
| KR20130100897A (ko) | 나노입자의 약제학적 조성물 | |
| CN1215589A (zh) | 用于治疗关节病的关节内制剂 | |
| CN104262638B (zh) | 透明质酸‑胱胺‑聚乳酸‑羟基乙酸接枝聚合物及其制备方法 | |
| Manimekalai et al. | Preparation and characterization of ceftriaxone sodium encapsulated chitosan nanoparticles | |
| Blanco et al. | Chitosan microspheres in PLG films as devices for cytarabine release | |
| WO2017039294A1 (ko) | 거대분자 기반 하이드로겔 조성물 및 이의 용도 | |
| Cao et al. | Preparation of surface‐modified, micrometer‐sized carboxymethyl chitosan drug‐loaded microspheres | |
| Papaneophytou et al. | Polyhydroxyalkanoates applications in drug carriers | |
| US20130071480A1 (en) | Particles which are surface coated with hyaluronan or one of the derivatives thereof and the use of same as biological vectors for active substances | |
| Oprea et al. | Synthesis and characterization of some cellulose/chondroitin sulphate hydrogels and their evaluation as carriers for drug delivery | |
| CN102225204A (zh) | 抗肿瘤的pH敏感缓释植入剂及制备方法 | |
| CN103520135A (zh) | 一种负载白藜芦醇的聚乳酸-羟基乙酸共聚物微纳米颗粒及其制备方法 | |
| CN113651959B (zh) | 一种基于氨基酸-羟基酸共聚物的纳米载药体系及其制备方法和应用 | |
| CN1939316B (zh) | 含阿霉素的微球及其制备方法 | |
| Kriplani et al. | Chitosan-a potential polymer to prepare anticancer drug delivery systems: Patent review | |
| Settu et al. | Formulation and evaluation of isorhamnetin loaded poly lactic-co-glycolic acid nanoparticles | |
| CN101983629B (zh) | 一种哌拉西林钠舒巴坦钠药物组合物微球注射剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20060302 |